DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lotensin HCT (Benazepril Hydrochloride / Hydrochlorothiazide) - Indications and Dosage



Lotensin HCT is indicated for the treatment of hypertension.

This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION).


Dose once daily. The dosage may then be increased after 2 to 3 weeks as needed to help achieve blood pressure goals. The maximum recommended dose is 20mg/25mg.

Switch Therapy:  A patient whose blood pressure is not adequately controlled with benazapril alone or with hydrochlorothiazide alone may be switched to combination therapy with Lotensin HCT. The usual recommended starting dose is 10/12.5 mg once daily to control blood pressure.

Replacement Therapy:  The combination may be substituted for the titrated individual components.


Lotensin HCT is available in tablets of four different strengths:

Benazepril   Hydrochlorothiazide   Tablet Color
5 mg 6.25 mg white
10 mg 12.5 mg light pink
20 mg 12.5 mg grayish-violet
20 mg 25 mg red

Tablets of each strength are supplied in bottles that contain a desiccant and 100 tablets.

      The National Drug Codes for the various packages are

Dose Bottle of 100 Tablet Imprint
5/6.25 NDC 0078-0451-05 57
10/12.5 NDC 0078-0452-05 72
20/12.5  NDC 0078-0453-05 74
20/25 NDC 0078-0454-05 75

Tablets are oblong and scored, with “Lotensin HCT” on one side and appropriate number imprinted on the other side.

Storage: Do not store above 30ºC (86ºF). Protect from moisture and light. Dispense in tight, light -resistant container (USP).

Manufactured by:
Novartis Pharmaceuticals Corporation
Suffern, New York 10901

Distributed by:
Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936

© Novartis

April 2013

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017